Literature DB >> 25904184

What's new about heparin-induced thrombocytopenia type II.

Yasser Sakr1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25904184     DOI： 10.1007/s00134-015-3811-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  23 in total

1.  Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.

Authors:  Andreas Greinacher; Manesh Gopinadhan; Jens-Uwe Günther; Mahmoud A Omer-Adam; Ulrike Strobel; Theodore E Warkentin; Georg Papastavrou; Werner Weitschies; Christiane A Helm
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-07-27       Impact factor: 8.311

Review 2.  Heparin-induced thrombocytopenia: towards consensus.

Authors:  T E Warkentin; B H Chong; A Greinacher
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

3.  Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.

Authors:  Henry Watson; Simon Davidson; David Keeling
Journal:  Br J Haematol       Date:  2012-10-09       Impact factor: 6.998

4.  External validation of the HIT Expert Probability (HEP) score.

Authors:  Lee Joseph; Marcelo P V Gomes; Firas Al Solaiman; Julie St John; Asuka Ozaki; Manjunath Raju; Manoj Dhariwal; Esther S H Kim
Journal:  Thromb Haemost       Date:  2015-01-15       Impact factor: 5.249

5.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  R H Aster
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

6.  New oral anticoagulants in the treatment of heparin-induced thrombocytopenia.

Authors:  Mohsen Sharifi; Curt Bay; Zoltan Vajo; Wilbur Freeman; Mirali Sharifi; Frederic Schwartz
Journal:  Thromb Res       Date:  2015-01-10       Impact factor: 3.944

7.  Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Dorothée Leroux; Nathalie Hezard; Aurélien Lebreton; Anne Bauters; Pierre Suchon; Emmanuel de Maistre; Christine Biron; Marie-Genevieve Huisse; Catherine Ternisien; Sophie Voisin; Yves Gruel; Claire Pouplard
Journal:  Br J Haematol       Date:  2014-05-12       Impact factor: 6.998

Review 8.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

9.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08

Review 10.  Heparin-induced thrombocytopenia in surgical patients.

Authors:  Sandra Battistelli; Alberto Genovese; Tommaso Gori
Journal:  Am J Surg       Date:  2010-01       Impact factor: 2.565
View more
  3 in total

1.  Focus on transfusion, bleeding and thrombosis.

Authors:  Elie Azoulay; Yaseen Arabi; Anders Perner
Journal:  Intensive Care Med       Date:  2016-10-25       Impact factor: 17.440

2.  Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study.

Authors:  Antoine Kimmoun; Walid Oulehri; Romain Sonneville; Paul-Henri Grisot; Elie Zogheib; Julien Amour; Nadia Aissaoui; Bruno Megarbane; Nicolas Mongardon; Amelie Renou; Matthieu Schmidt; Emmanuel Besnier; Clément Delmas; Geraldine Dessertaine; Catherine Guidon; Nicolas Nesseler; Guylaine Labro; Bertrand Rozec; Marc Pierrot; Julie Helms; David Bougon; Laurent Chardonnal; Anne Medard; Alexandre Ouattara; Nicolas Girerd; Zohra Lamiral; Marc Borie; Nadine Ajzenberg; Bruno Levy
Journal:  Intensive Care Med       Date:  2018-08-22       Impact factor: 17.440

3.  PF4-heparin antibodies during ECMO: incidence, course, and outcomes.

Authors:  Florent Laverdure; Virginie Louvain-Quintard; Talna Kortchinsky; Saïda Rezaiguïa-Delclaux; Audrey Imbert; François Stéphan
Journal:  Intensive Care Med       Date:  2016-02-22       Impact factor: 17.440
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.